U.S.: In-Vitro Diagnostic Substance Market 2024

In-Vitro Diagnostic Substance Market Size in the U.S.

The U.S. in-vitro diagnostic substance market soared to $X in 2022, surging by X% against the previous year. Over the period under review, consumption showed a strong increase. As a result, consumption attained the peak level and is likely to continue growth in the immediate term.

In-Vitro Diagnostic Substance Production in the U.S.

In value terms, in-vitro diagnostic substance production shrank slightly to $X in 2022. The total output value increased at an average annual rate of X% from 2013 to 2022; the trend pattern remained consistent, with somewhat noticeable fluctuations in certain years. The growth pace was the most rapid in 2020 when the production volume increased by X% against the previous year. In-vitro diagnostic substance production peaked at $X in 2021, and then dropped modestly in the following year.

In-Vitro Diagnostic Substance Exports

Exports from the U.S.

In 2022, the amount of in-vitro diagnostic substances exported from the United States reached X tons, with an increase of X% on the previous year. Overall, exports posted a remarkable increase. The most prominent rate of growth was recorded in 2020 with an increase of X%. Over the period under review, the exports attained the peak figure in 2022 and are expected to retain growth in years to come.

In value terms, in-vitro diagnostic substance exports expanded to $X in 2022. Over the period under review, exports saw a buoyant increase. The most prominent rate of growth was recorded in 2020 with an increase of X%. The exports peaked in 2022 and are likely to see steady growth in years to come.

Exports by Country

Germany (X tons), China (X tons) and Canada (X tons) were the main destinations of in-vitro diagnostic substance exports from the United States, with a combined X% share of total exports. The Netherlands, Italy, France, Brazil, Japan, Mexico, Belgium, South Korea, India and Australia lagged somewhat behind, together accounting for a further X%.

From 2013 to 2022, the biggest increases were recorded for Italy (with a CAGR of X%), while shipments for the other leaders experienced more modest paces of growth.

In value terms, the largest markets for in-vitro diagnostic substance exported from the United States were Germany ($X), China ($X) and the Netherlands ($X), with a combined X% share of total exports.

The Netherlands, with a CAGR of X%, saw the highest rates of growth with regard to the value of exports, among the main countries of destination over the period under review, while shipments for the other leaders experienced more modest paces of growth.

Export Prices by Country

The average in-vitro diagnostic substance export price stood at $X per ton in 2022, which is down by X% against the previous year. Over the period under review, the export price continues to indicate a abrupt downturn. The pace of growth was the most pronounced in 2019 an increase of X%. As a result, the export price attained the peak level of $X per ton. From 2020 to 2022, the average export prices remained at a somewhat lower figure.

There were significant differences in the average prices for the major export markets. In 2022, amid the top suppliers, the country with the highest price was Japan ($X per ton), while the average price for exports to Belgium ($X per ton) was amongst the lowest.

From 2013 to 2022, the most notable rate of growth in terms of prices was recorded for supplies to South Korea (X%), while the prices for the other major destinations experienced mixed trend patterns.

In-Vitro Diagnostic Substance Imports

Imports into the U.S.

In 2022, purchases abroad of in-vitro diagnostic substances increased by X% to X tons, rising for the third consecutive year after two years of decline. Over the period under review, imports posted strong growth. As a result, imports reached the peak and are likely to continue growth in the immediate term.

In value terms, in-vitro diagnostic substance imports skyrocketed to $X in 2022. In general, imports continue to indicate a significant expansion. As a result, imports reached the peak and are likely to continue growth in the immediate term.

Imports by Country

In 2022, China (X tons) constituted the largest in-vitro diagnostic substance supplier to the United States, accounting for a X% share of total imports. Moreover, in-vitro diagnostic substance imports from China exceeded the figures recorded by the second-largest supplier, Germany (X tons), fivefold. Canada (X tons) ranked third in terms of total imports with a X% share.

From 2013 to 2022, the average annual rate of growth in terms of volume from China amounted to X%. The remaining supplying countries recorded the following average annual rates of imports growth: Germany (X% per year) and Canada (X% per year).

In value terms, Ireland ($X), Germany ($X) and China ($X) constituted the largest in-vitro diagnostic substance suppliers to the United States, with a combined X% share of total imports. Japan, the UK, South Korea, Canada, Norway, Italy, Sweden, France, Mexico and Hong Kong SAR lagged somewhat behind, together accounting for a further X%.

In terms of the main suppliers, Hong Kong SAR, with a CAGR of X%, recorded the highest rates of growth with regard to the value of imports, over the period under review, while purchases for the other leaders experienced more modest paces of growth.

Import Prices by Country

The average in-vitro diagnostic substance import price stood at $X per ton in 2022, increasing by X% against the previous year. Over the period under review, the import price recorded a strong expansion. As a result, import price attained the peak level and is likely to continue growth in the immediate term.

Prices varied noticeably by country of origin: amid the top importers, the country with the highest price was Ireland ($X,801 per ton), while the price for Mexico ($X per ton) was amongst the lowest.

From 2013 to 2022, the most notable rate of growth in terms of prices was attained by Ireland (X%), while the prices for the other major suppliers experienced more modest paces of growth.

Source: IndexBox Platform

Frequently Asked Questions (FAQ) :